In patients with mostly undifferentiated pleomorphic sarcomas, 2-year DFS with the addition of preoperative and postoperative pembrolizumab (Keytruda) infusions reached 67%, as compared with 52% with ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family ...

Malignant fibrous histiocytoma (MFH) is a type of cancer that typically occurs in soft tissues, such as the muscles and tendons. When it starts in the bones, doctors call it MFH of the bone. The up-to ...

In soft tissue sarcomas, the diagnosis of malignant fibrous histiocytoma (MFH) has been a very controversial issue, and MFH is now considered to be reclassified into pleomorphic subtypes of other ...

Pancreatic Proteolytic Enzyme Therapy Compared With Gemcitabine-Based Chemotherapy for the Treatment of Pancreatic Cancer One hundred thirty primary RASs were identified from 7,649 STS patients from ...

— Mec-V demonstrates median OS of 21.5 months in patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma compared with approximately 12 months with ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. A 56-year-old man presented to the ED with 3 months of ...

Keytruda is showing benefit to some patients with sarcoma, according to interim results from a phase 2 trial. According to interim results from the phase 2 SARC-028 trial, Keytruda (pembrolizumab) ...

Sarcomas - cancers of the connective tissues like muscles, joints, fat and bone - come in dozens of subtypes. Clinical trial results have been mixed when treating these diverse tumors with ...

Please provide your email address to receive an email when new articles are posted on . A phase 2 trial conducted by researchers at The University of Texas MD Anderson Cancer Center demonstrated the ...